TPIDB > Principal Investigator
Principal Investigator
更新時間：2025-03-04
黃立民Huang, Li-Min
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
42Publications
21
Lee HY, Lu CY, Lee PI, Chen JM, Huang LM, Chang LY. Pneumocystis jiroveci pneumonia in Taiwan from 2014 to 2017: Clinical manifestations and outcomes between pediatric and adult patients. J Microbiol Immunol Infect. 2019 Dec;52(6):983-990. doi: 10.1016/j.jmii.2019.05.003. Epub 2019 May 22. PMID: 31164278.
22
Lee JT, Shih WL, Yen TY, Cheng AL, Lu CY, Chang LY, Huang LM. Enterovirus D68 seroepidemiology in Taiwan, a cross sectional study from 2017. PLoS One. 2020 Mar 10;15(3):e0230180. doi: 10.1371/journal.pone.0230180. PMID: 32155216; PMCID: PMC7064212.
23
Lee JT, Yen TY, Shih WL, Lu CY, Liu DP, Huang YC, Chang LY, Huang LM, Lin TY. Enterovirus 71 seroepidemiology in Taiwan in 2017 and comparison of those rates in 1997, 1999 and 2007. PLoS One. 2019 Oct 17;14(10):e0224110. doi: 10.1371/journal.pone.0224110. PMID: 31622436; PMCID: PMC6797108.
24
Lee KL, Lee CM, Yang TL, Yen TY, Chang LY, Chen JM, Lee PI, Huang LM, Lu CY. Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019. J Formos Med Assoc. 2021 Jan;120(1 Pt 1):281-291. doi: 10.1016/j.jfma.2020.08.018. Epub 2020 Sep 15. PMID: 32948415.
25
Lin GL, Lu CY, Chen JM, Lee PI, Ho SY, Weng KC, Huang LM, Chang LY. Molecular epidemiology and clinical features of adenovirus infection in Taiwanese children, 2014. J Microbiol Immunol Infect. 2019 Apr;52(2):215-224. doi: 10.1016/j.jmii.2018.07.005. Epub 2018 Aug 18. PMID: 30172758.
26
Lin HH, Huang LM, Wu SC. A quantitative luciferase-based cell-cell fusion assay to measure four-serotype dengue virus E protein-triggered membrane fusion. Hum Vaccin Immunother. 2020 Sep 1;16(9):2176-2182. doi: 10.1080/21645515.2020.1748989. Epub 2020 Jun 12. PMID: 32530355; PMCID: PMC7553686.
27
Lu CY, Chiang CS, Chiu CH, Wang ET, Chen YY, Yao SM, Chang LY, Huang LM, Lin TY, Chou JH. Successful Control of Streptococcus pneumoniae 19A Replacement With a Catch-up Primary Vaccination Program in Taiwan. Clin Infect Dis. 2019 Oct 15;69(9):1581-1587. doi: 10.1093/cid/ciy1127. PMID: 30923808.
28
Lu CY, Chung CH, Huang LM, Kruger E, Tan SC, Zhang XH, Chiu NC. Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan. Cost Eff Resour Alloc. 2020 Aug 28;18:30. doi: 10.1186/s12962-020-00225-9. Erratum in: Cost Eff Resour Alloc. 2021 May 17;19(1):30. PMID: 32874139; PMCID: PMC7456386.
29
Lu CY, Yen TY, Chang LY, Liau YJ, Liu HH, Huang LM. Multiple-locus variable-number tandem-repeat analysis (MLVA) of macrolide-susceptible and -resistant Mycoplasma pneumoniae in children in Taiwan. J Formos Med Assoc. 2020 Oct;119(10):1539-1545. doi: 10.1016/j.jfma.2019.12.008. Epub 2020 Jan 8. PMID: 31924377.
Copy
Copy
30
Schwarz TF, Huang LM, Valencia A, Panzer F, Chiu CH, Decreux A, Poncelet S, Karkada N, Folschweiller N, Lin L, Dubin G, Struyf F. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Hum Vaccin Immunother. 2019;15(7-8):1970-1979. doi: 10.1080/21645515.2019.1625644. Epub 2019 Jul 17. PMID: 31268383; PMCID: PMC6746471.
